Camicinal (GSK962040) is primarily investigated for its potential therapeutic applications in gastrointestinal motility disorders. It acts as a motilin receptor agonist, which stimulates contractions in the stomach and upper gastrointestinal tract. This mechanism makes it a promising candidate for treating conditions like gastroparesis, a disorder characterized by delayed gastric emptying, often seen in patients with diabetes or post-surgical complications. By enhancing gastric motility, it may alleviate symptoms such as nausea, vomiting, bloating, and early satiety. Additionally, it has been explored for its potential use in improving feeding intolerance in critically ill patients, where gastrointestinal function is often compromised. Research is ongoing to evaluate its efficacy and safety in these clinical settings.